國立虎尾科技大學 |

The duration and safety of osteoporosis treatment = anabolic and antiresorptive therapy /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	The duration and safety of osteoporosis treatment/ edited by Stuart L. Silverman, Bo Abrahamsen.
Reminder of title:	anabolic and antiresorptive therapy /
other author:	Silverman, Stuart.
Published:	Cham :Springer International Publishing : : 2016.,
Description:	xvi, 338 p. :ill. (some col.), digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Osteoporosis - Treatment -
Online resource:	http://dx.doi.org/10.1007/978-3-319-23639-1
ISBN:	9783319236391

The duration and safety of osteoporosis treatment = anabolic and antiresorptive therapy /
The duration and safety of osteoporosis treatmentanabolic and antiresorptive therapy /[electronic resource] :edited by Stuart L. Silverman, Bo Abrahamsen. - Cham :Springer International Publishing :2016. - xvi, 338 p. :ill. (some col.), digital ;24 cm.

Foreword -- Preface -- Osteoporosis: Pathophysiology & Epidemiology -- Antiresorptives -- Anabolics -- Tools for Assessing Fracture Risk and for Treatment Monitoring -- Treatment Failure -- Epidemiology of Atypical Subtrochanteric and Femoral Shaft Fractures -- Bisphosphonate-Related Atypical Femoral Fractures and Their Radiographic Features -- Factors Contributing to Atypical Femoral Fractures -- Clinical Presentation of Atypical Femur Fractures -- Effects of Antiresorptive Therapy on Bone Microarchitecture -- Management of Atypical Femoral Fractures -- Osteonecrosis of the Jaw: Clinico-Pathologic and Radiologic Features -- Epidemiology of Osteonecrosis of the Jaws from Antiresorptive Treatment -- Management of Osteonecrosis of the Jaw in Patients Receiving Antiresorptive Treatment -- Long-Term Efficacy and Safety of Treatments for Osteoporosis -- Management of Drug Holidays -- Patients Who Do Not Take Their Osteoporosis Medications: Can We Help Them Become Compliant? -- Fractures and Healing on Antiresorptive Therapy -- Antiresorptive Therapy and Mortality and Cancer Incidence -- Other Safety Concerns -- The Impact of Regulatory and Scientific Organizations Recommendations on Clinical Decision Making -- Integrated Clinical View on Long-Term Management of Patients with Osteoporosis -- Conclusions.

Providing a comprehensive review of short-and long-term adverse events of both antiresorptive and anabolic drugs, this practical guide updates the clinician on the pathophysiology of osteoporosis and the principles behind our present and future pharmaceuticals. Leading practitioners in the field examine all current literature and data regarding the duration and safety of these therapies, with recommendations for clinicians on decision-making and best practices for osteoporosis patients. An overview of the pathophysiology and epidemiology of osteoporosis and discussion of both anabolic and antiresorptive drugs is followed by fracture risk assessment and an examination of treatment failures. Next, a number of chapters are dedicated to the diagnosis, presentation and management of atypical femur fractures and osteonecrosis of the jaw (ONJ), each of which are significant patient concerns when using these osteoporosis treatments. The introduction and utilization of drug holidays is also discussed, as well as the long-term outlook for management of osteoporotic patients. Written and edited by experts in the field, The Duration and Safety of Osteoporosis Treatment is a balanced resource for researchers, practitioners and policy-makers alike for clinical decision-making and patient care.

ISBN: 9783319236391

Standard No.: 10.1007/978-3-319-23639-1doiSubjects--Topical Terms:

1104309
Osteoporosis
--Treatment

LC Class. No.: RC931.O73

Dewey Class. No.: 616.71606

The duration and safety of osteoporosis treatment = anabolic and antiresorptive therapy /
LDR:03615nam a2200313 a 4500 001 861711
003 DE-He213
005 20160810093732.0
006 m d
007 cr nn 008maaau
008 170720s2016 gw s 0 eng d
020 $a 9783319236391 $q (electronic bk.)
020 $a 9783319236384 $q (paper)
024 7 $a 10.1007/978-3-319-23639-1 $2 doi
035 $a 978-3-319-23639-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC931.O73
072 7 $a MJG $2 bicssc
072 7 $a MED027000 $2 bisacsh
082 0 4 $a 616.71606 $2 23
090 $a RC931.O73 $b D952 2016
245 0 4 $a The duration and safety of osteoporosis treatment $h [electronic resource] : $b anabolic and antiresorptive therapy / $c edited by Stuart L. Silverman, Bo Abrahamsen.
260 $a Cham : $c 2016. $b Springer International Publishing : $b Imprint: Springer,
300 $a xvi, 338 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a Foreword -- Preface -- Osteoporosis: Pathophysiology & Epidemiology -- Antiresorptives -- Anabolics -- Tools for Assessing Fracture Risk and for Treatment Monitoring -- Treatment Failure -- Epidemiology of Atypical Subtrochanteric and Femoral Shaft Fractures -- Bisphosphonate-Related Atypical Femoral Fractures and Their Radiographic Features -- Factors Contributing to Atypical Femoral Fractures -- Clinical Presentation of Atypical Femur Fractures -- Effects of Antiresorptive Therapy on Bone Microarchitecture -- Management of Atypical Femoral Fractures -- Osteonecrosis of the Jaw: Clinico-Pathologic and Radiologic Features -- Epidemiology of Osteonecrosis of the Jaws from Antiresorptive Treatment -- Management of Osteonecrosis of the Jaw in Patients Receiving Antiresorptive Treatment -- Long-Term Efficacy and Safety of Treatments for Osteoporosis -- Management of Drug Holidays -- Patients Who Do Not Take Their Osteoporosis Medications: Can We Help Them Become Compliant? -- Fractures and Healing on Antiresorptive Therapy -- Antiresorptive Therapy and Mortality and Cancer Incidence -- Other Safety Concerns -- The Impact of Regulatory and Scientific Organizations Recommendations on Clinical Decision Making -- Integrated Clinical View on Long-Term Management of Patients with Osteoporosis -- Conclusions.
520 $a Providing a comprehensive review of short-and long-term adverse events of both antiresorptive and anabolic drugs, this practical guide updates the clinician on the pathophysiology of osteoporosis and the principles behind our present and future pharmaceuticals. Leading practitioners in the field examine all current literature and data regarding the duration and safety of these therapies, with recommendations for clinicians on decision-making and best practices for osteoporosis patients. An overview of the pathophysiology and epidemiology of osteoporosis and discussion of both anabolic and antiresorptive drugs is followed by fracture risk assessment and an examination of treatment failures. Next, a number of chapters are dedicated to the diagnosis, presentation and management of atypical femur fractures and osteonecrosis of the jaw (ONJ), each of which are significant patient concerns when using these osteoporosis treatments. The introduction and utilization of drug holidays is also discussed, as well as the long-term outlook for management of osteoporotic patients. Written and edited by experts in the field, The Duration and Safety of Osteoporosis Treatment is a balanced resource for researchers, practitioners and policy-makers alike for clinical decision-making and patient care.
650 0 $a Osteoporosis $x Treatment $x Complications. $3 1104309
650 1 4 $a Medicine & Public Health. $3 593949
650 2 4 $a Endocrinology. $3 645497
650 2 4 $a Orthopedics. $3 596623
700 1 $a Silverman, Stuart. $3 1104307
700 1 $a Abrahamsen, Bo. $3 1104308
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-23639-1
950 $a Medicine (Springer-11650)